Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

87.02USD
1:10pm EST
Change (% chg)

$-0.28 (-0.33%)
Prev Close
$87.30
Open
$87.30
Day's High
$87.30
Day's Low
$86.68
Volume
4,163,386
Avg. Vol
7,902,123
52-wk High
$106.67
52-wk Low
$58.59

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $108,911.00
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 43.29 30.48 33.71
EPS (TTM): 3.22 -- --
ROI: 10.08 14.98 14.48
ROE: 37.19 16.31 15.99

Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal

Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.

Jan 04 2019

Celgene, Bristol-Myers set $2.2 bln termination fee for their mega deal

Jan 4 Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger announced on Thursday, according to a regulatory filing.

Jan 04 2019

BRIEF-Ribon Therapeutics Raises $65 Mln

* RIBON THERAPEUTICS - RAISED $65 MILLION IN FINANCING LED BY NOVARTIS VENTURE FUND, WITH JOHNSON & JOHNSON INNOVATION - JJDC, CELGENE, EXISTING INVESTORS

Jan 04 2019

Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever. | Video

Jan 04 2019

UPDATE 7-Bristol-Myers to buy Celgene for $74 bln in largest biopharma deal

Jan 3 Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever.

Jan 03 2019

Grant & Eisenhofer settles fee fight with Celgene whistleblower

The law firm Grant & Eisenhofer has agreed to settle a lawsuit it filed in 2017 in a bid to obtain a cut of the $78 million that a former whistleblower client was awarded for her role in securing a $280 million settlement with drugmaker Celgene Corp.

Jan 03 2019

Breakingviews - Bristol-Myers takes $74 bln bet against the market

NEW YORK (Reuters Breakingviews) - Bristol-Myers Squibb is taking a $74 billion bet against the market. There are good reasons to buy rival oncology giant Celgene. But cost cuts don’t cover the 54 percent premium, and the target’s owners get the financial benefit. Bristol is hoping for luck in the courts and multiple regulatory approvals that Celgene’s shareholders were skeptical of.

Jan 03 2019

Father and son advised on opposite sides of Bristol-Celgene deal

For most U.S. families, the holidays are all about gathering around the fireplace, overeating at festive dinners, and playing the occasional board game. But this year, a father and son were also working on the biggest pharmaceutical acquisition of all time.

Jan 03 2019

Father and son advised on opposite sides of Bristol-Celgene deal

Jan 3 For most U.S. families, the holidays are all about gathering around the fireplace, overeating at festive dinners, and playing the occasional board game. But this year, a father and son were also working on the biggest pharmaceutical acquisition of all time.

Jan 03 2019

Cost to insure Bristol-Myers debt jumps as leverage balloons

NEW YORK The cost to insure Bristol-Myers Squibb debt hit its highest point since May 2010 on Thursday, following the announcement that the U.S. pharmaceutical company would acquire rival Celgene Corp in a deal worth about $74 billion.

Jan 03 2019

Earnings vs. Estimates